Becton Dickinson and (BDX)

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The company aims to do just that.

While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metric...

Becton Dickinson (BDX) came out with quarterly earnings of $3.43 per share, beating the Zacks Consensus Estimate of $2.98 per share. This compares to earnings of $2.68 per share a year ago.

Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business.

The continued solid uptake of BD's products is expected to have driven fiscal first-quarter revenues despite transitory market dynamics.

Besides Wall Street's top -and-bottom-line estimates for Becton Dickinson (BDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared durin...

Activist investor Starboard Value has taken a stake in Becton Dickinson and is pushing the medical technology company to sell its life sciences unit, the Financial Times reported on Monday.

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.